INTRA-CELLULAR THERAPIES INC (ITCI) Stock Fundamental Analysis

NASDAQ:ITCI • US46116X1019

131.87 USD
-0.05 (-0.04%)
At close: Apr 1, 2025
131.92 USD
+0.05 (+0.04%)
After Hours: 4/1/2025, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

Overall ITCI gets a fundamental rating of 5 out of 10. We evaluated ITCI against 193 industry peers in the Pharmaceuticals industry. While ITCI has a great health rating, there are worries on its profitability. ITCI is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • ITCI had negative earnings in the past year.
  • In the past year ITCI has reported a negative cash flow from operations.
  • ITCI had negative earnings in each of the past 5 years.
  • In the past 5 years ITCI always reported negative operating cash flow.
ITCI Yearly Net Income VS EBIT VS OCF VS FCFITCI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

  • ITCI has a Return On Assets of -5.46%. This is in the better half of the industry: ITCI outperforms 73.37% of its industry peers.
  • ITCI has a better Return On Equity (-6.50%) than 78.39% of its industry peers.
Industry RankSector Rank
ROA -5.46%
ROE -6.5%
ROIC N/A
ROA(3y)-19.53%
ROA(5y)-29.65%
ROE(3y)-23.06%
ROE(5y)-34.34%
ROIC(3y)N/A
ROIC(5y)N/A
ITCI Yearly ROA, ROE, ROICITCI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

  • With an excellent Gross Margin value of 91.63%, ITCI belongs to the best of the industry, outperforming 94.97% of the companies in the same industry.
  • ITCI's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for ITCI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 91.63%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.43%
GM growth 5YN/A
ITCI Yearly Profit, Operating, Gross MarginsITCI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50K -100K -150K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • ITCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, ITCI has more shares outstanding
  • Compared to 5 years ago, ITCI has more shares outstanding
  • ITCI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ITCI Yearly Shares OutstandingITCI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ITCI Yearly Total Debt VS Total AssetsITCI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • ITCI has an Altman-Z score of 38.03. This indicates that ITCI is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of ITCI (38.03) is better than 97.49% of its industry peers.
  • ITCI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 38.03
ROIC/WACCN/A
WACC9.49%
ITCI Yearly LT Debt VS Equity VS FCFITCI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

  • ITCI has a Current Ratio of 6.36. This indicates that ITCI is financially healthy and has no problem in meeting its short term obligations.
  • ITCI has a better Current ratio (6.36) than 76.38% of its industry peers.
  • A Quick Ratio of 6.23 indicates that ITCI has no problem at all paying its short term obligations.
  • ITCI has a better Quick ratio (6.23) than 76.88% of its industry peers.
Industry RankSector Rank
Current Ratio 6.36
Quick Ratio 6.23
ITCI Yearly Current Assets VS Current LiabilitesITCI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • ITCI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 50.00%, which is quite impressive.
  • The Revenue has grown by 46.61% in the past year. This is a very strong growth!
  • ITCI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 484.27% yearly.
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.67%
Revenue 1Y (TTM)46.61%
Revenue growth 3Y101.03%
Revenue growth 5Y484.27%
Sales Q2Q%50.81%

3.2 Future

  • The Earnings Per Share is expected to grow by 87.04% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, ITCI will show a very strong growth in Revenue. The Revenue will grow by 37.51% on average per year.
EPS Next Y127.35%
EPS Next 2Y174.17%
EPS Next 3Y140.69%
EPS Next 5Y87.04%
Revenue Next Year40.33%
Revenue Next 2Y50.81%
Revenue Next 3Y47.62%
Revenue Next 5Y37.51%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ITCI Yearly Revenue VS EstimatesITCI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B
ITCI Yearly EPS VS EstimatesITCI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10 15

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • ITCI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • The Price/Forward Earnings ratio is 660.59, which means the current valuation is very expensive for ITCI.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of ITCI indicates a somewhat cheap valuation: ITCI is cheaper than 73.37% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 28.05. ITCI is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 660.59
ITCI Price Earnings VS Forward Price EarningsITCI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 200 400 600

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ITCI Per share dataITCI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates ITCI does not grow enough to justify the current Price/Earnings ratio.
  • A more expensive valuation may be justified as ITCI's earnings are expected to grow with 140.69% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y174.17%
EPS Next 3Y140.69%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ITCI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

INTRA-CELLULAR THERAPIES INC

NASDAQ:ITCI (4/1/2025, 8:00:02 PM)

After market: 131.92 +0.05 (+0.04%)

131.87

-0.05 (-0.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-21
Earnings (Next)05-05
Inst Owners94.75%
Inst Owner Change-99.55%
Ins Owners0.23%
Ins Owner Change0%
Market Cap14.05B
Revenue(TTM)680.85M
Net Income(TTM)-74.68M
Analysts72.22
Price Target133.21 (1.02%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-32.8%
Min EPS beat(2)-40.63%
Max EPS beat(2)-24.97%
EPS beat(4)2
Avg EPS beat(4)0.62%
Min EPS beat(4)-40.63%
Max EPS beat(4)50.59%
EPS beat(8)6
Avg EPS beat(8)17.95%
EPS beat(12)9
Avg EPS beat(12)16.57%
EPS beat(16)10
Avg EPS beat(16)13.07%
Revenue beat(2)1
Avg Revenue beat(2)0.38%
Min Revenue beat(2)-0.24%
Max Revenue beat(2)1%
Revenue beat(4)3
Avg Revenue beat(4)0.36%
Min Revenue beat(4)-0.24%
Max Revenue beat(4)1%
Revenue beat(8)6
Avg Revenue beat(8)0.51%
Revenue beat(12)9
Avg Revenue beat(12)1.93%
Revenue beat(16)11
Avg Revenue beat(16)1.25%
PT rev (1m)-0.1%
PT rev (3m)26.18%
EPS NQ rev (1m)0%
EPS NQ rev (3m)42.86%
EPS NY rev (1m)-30.48%
EPS NY rev (3m)-47.79%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.15%
Revenue NY rev (1m)0.91%
Revenue NY rev (3m)1.41%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 660.59
P/S 20.63
P/FCF N/A
P/OCF N/A
P/B 12.23
P/tB 12.23
EV/EBITDA N/A
EPS(TTM)-0.73
EYN/A
EPS(NY)0.2
Fwd EY0.15%
FCF(TTM)-0.69
FCFYN/A
OCF(TTM)-0.69
OCFYN/A
SpS6.39
BVpS10.78
TBVpS10.78
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -5.46%
ROE -6.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 91.63%
FCFM N/A
ROA(3y)-19.53%
ROA(5y)-29.65%
ROE(3y)-23.06%
ROE(5y)-34.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.43%
GM growth 5YN/A
F-Score4
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 63.39%
Cap/Sales 0.05%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.36
Quick Ratio 6.23
Altman-Z 38.03
F-Score4
WACC9.49%
ROIC/WACCN/A
Cap/Depr(3y)77.5%
Cap/Depr(5y)69.14%
Cap/Sales(3y)0.14%
Cap/Sales(5y)0.4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.67%
EPS Next Y127.35%
EPS Next 2Y174.17%
EPS Next 3Y140.69%
EPS Next 5Y87.04%
Revenue 1Y (TTM)46.61%
Revenue growth 3Y101.03%
Revenue growth 5Y484.27%
Sales Q2Q%50.81%
Revenue Next Year40.33%
Revenue Next 2Y50.81%
Revenue Next 3Y47.62%
Revenue Next 5Y37.51%
EBIT growth 1Y26.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year126.61%
EBIT Next 3Y133.69%
EBIT Next 5Y90.06%
FCF growth 1Y40.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y41.08%
OCF growth 3YN/A
OCF growth 5YN/A

INTRA-CELLULAR THERAPIES INC / ITCI FAQ

Can you provide the ChartMill fundamental rating for INTRA-CELLULAR THERAPIES INC?

ChartMill assigns a fundamental rating of 5 / 10 to ITCI.


What is the valuation status of INTRA-CELLULAR THERAPIES INC (ITCI) stock?

ChartMill assigns a valuation rating of 1 / 10 to INTRA-CELLULAR THERAPIES INC (ITCI). This can be considered as Overvalued.


Can you provide the profitability details for INTRA-CELLULAR THERAPIES INC?

INTRA-CELLULAR THERAPIES INC (ITCI) has a profitability rating of 2 / 10.


Can you provide the financial health for ITCI stock?

The financial health rating of INTRA-CELLULAR THERAPIES INC (ITCI) is 8 / 10.